Literature DB >> 15315852

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.

David W C Beasley1, Li Li, Miguel T Suderman, Farshad Guirakhoo, Dennis W Trent, Thomas P Monath, Robert E Shope, Alan D T Barrett.   

Abstract

The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax-JE, and the currently licensed vaccine, JE-VAX, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax-JE stimulated protection that was comparable or superior to the JE-VAX control.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15315852     DOI： 10.1016/j.vaccine.2004.03.027

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  30 in total

Review 1.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

2.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

3.  Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Authors:  Peter E Nasveld; Joanne Marjason; Sonya Bennett; John Aaskov; Suzanne Elliott; Karen McCarthy; Niranjan Kanesa-Thasan; Emmanuel Feroldi; Mark Reid
Journal:  Hum Vaccin       Date:  2010-11-01

4.  Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Authors:  Peter E Nasveld; Andrew Ebringer; Nathan Elmes; Sonya Bennett; Sutee Yoksan; John Aaskov; Karen McCarthy; Niranjan Kanesa-thasan; Claude Meric; Mark Reid
Journal:  Hum Vaccin       Date:  2010-12-01

5.  Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.

Authors:  Douglas G Widman; Tomohiro Ishikawa; Luis D Giavedoni; Vida L Hodara; Melissa de la Garza; Jessica A Montalbo; Amelia P Travassos Da Rosa; Robert B Tesh; Jean L Patterson; Ricardo Carrion; Nigel Bourne; Peter W Mason
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

6.  Development of a vaccine to prevent Japanese encephalitis: a brief review.

Authors:  Viroj Wiwanitkit
Journal:  Int J Gen Med       Date:  2009-12-29

7.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

8.  Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody.

Authors:  Ching-Juh Lai; Ana P Goncalvez; Ruhe Men; Claire Wernly; Olivia Donau; Ronald E Engle; Robert H Purcell
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Japanese Encephalitis Vaccines.

Authors:  Monica A McArthur; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011-09-25

10.  Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; Christopher T Hanson; Stephen S Whitehead
Journal:  Vaccine       Date:  2014-03-31       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.